English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 850021      Online Users : 730
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/6739


    Title: Immunological evaluation and comparison of different EV71 vaccine candidates
    Authors: Chou, AH;Liu, CC;Chang, JY;Lien, SP;Guo, MS;Tasi, HP;Hsiao, KN;Liu, SJ;Sia, C;Wu, SC;Lee, MS;Hsiao, CH;Wang, JR;Chow, YH;Chong, P
    Contributors: Division of Vaccine Research and Development
    Abstract: Enterovirus 71 (EV71) and coxsackievirus A16 (CVA16) are major causative agents of hand, foot, and mouth diseases (HFMDs), and EV71 is now recognized as an emerging neurotropic virus in Asia. Effective medications and/or prophylactic vaccines against HFMD are not available. The current results from mouse immunogenicity studies using in-house standardized RD cell virus neutralization assays indicate that (1) VP1 peptide (residues 211–225) formulated with Freund’s adjuvant (CFA/IFA) elicited low virus neutralizing antibody response (1/32 titer); (2) recombinant virus-like particles produced from baculovirus formulated with CFA/IFA could elicit good virus neutralization titer (1/160); (3) individual recombinant EV71 antigens (VP1, VP2, and VP3) formulated with CFA/IFA, only VP1 elicited antibody response with 1/128 virus neutralization titer; and (4) the formalin-inactivated EV71 formulated in alum elicited antibodies that cross-neutralized different EV71 genotypes (1/640), but failed to neutralize CVA16. In contrast, rabbits antisera could cross-neutralize strongly against different genotypes of EV71 but weakly against CVA16, with average titers 1/6400 and 1/32, respectively. The VP1 amino acid sequence dissimilarity between CVA16 and EV71 could partially explain why mouse antibodies failed to cross-neutralize CVA16. Therefore, the best formulation for producing cost-effective HFMD vaccine is a combination of formalin-inactivated EV71 and CAV16 virions.
    Date: 2012-09
    Relation: Clinical and Developmental Immunology. 2012 Sep;2012:Article ID 831282.
    Link to: http://dx.doi.org/10.1155/2012/831282
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000309012400001
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84867388819
    Appears in Collections:[莊再成] 期刊論文
    [謝鐸源(2006-2014)] 期刊論文
    [周彥宏] 期刊論文
    [劉士任] 期刊論文
    [劉家齊] 期刊論文
    [李敏西] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PB2012102510.pdf567KbAdobe PDF689View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback